Evidence. I was a contributor to a recent commentary questioning whether the USP25 gene should currently be considered a validated gene for genetic generalized epilepsy. The motivation behind this commentary was not to challenge the initial data, but to ask what happens when a claim for gene validity encounters the full weight of accumulating evidence. Does USP25 remain robust as our expectations for validation rise? Or has it reached the point where additional evidence no longer supports the initial discovery?